OPKO Health Releases Q4 2024 Business Highlights and Financial Results

February 27, 2025

OPKO Health, a prominent healthcare company, had a notably successful fourth quarter in 2024. Several key achievements were highlighted during this period, showcasing the company’s dedication to advancing various therapeutic treatments.

Merck, in collaboration with OPKO, initiated a Phase 1 trial for an Epstein-Barr virus (EBV) vaccine candidate. This vaccine is being tested for safety and tolerability in a group of healthy adults. ModeX’s ferritin nanoparticle technology is central to the development of this vaccine. Upon the commencement of this trial, ModeX received a milestone payment, signifying progress in combating EBV.

Furthermore, ModeX was awarded an additional $51 million by BARDA for the development of multispecific antibodies for COVID-19 and to begin work on an influenza program. This funding supports the progression of a second novel multispecific antibody to SARS-CoV-2 through preclinical and Phase 1 trials. BARDA also triggered a second phase of funding, allowing ModeX to delve into developing influenza multispecifics utilizing gene and protein delivery mechanisms.

OPKO also made headway with its MDX2001 Phase 1 trial targeting solid tumor cancers. This tetraspecific antibody, designed to bolster T-cell function while preventing tumor antigen escape, is currently in the enrollment phase. This innovative therapy aims to optimize cancer treatment outcomes by enhancing the body’s immune response against tumors.

NGENLA®, a growth hormone product co-marketed with Pfizer, continued its global commercialization efforts, now available in major markets worldwide. OPKO stands to benefit from a share of gross profits generated from sales of NGENLA and Pfizer’s Genotropin®. This partnership exemplifies OPKO’s success in making impactful contributions to the healthcare industry.

Additionally, BioReference Health, an OPKO subsidiary, made significant strides towards profitability in recent months. By focusing on reducing costs and enhancing revenue from specialty testing segments, BioReference aims to achieve sustainable growth and profitability by the end of 2025. In line with this goal, OPKO divested a portion of BioReference Health’s laboratory testing business in 2024, further streamlining its operations.

OPKO also undertook strategic financial restructuring during the fourth quarter of 2024. By repurchasing convertible notes and engaging in transactions to realign its capital structure, the company aims to enhance its liquidity and flexibility. This financial maneuvering is crucial for enabling OPKO to execute its long-term plans and continue making groundbreaking advancements in the healthcare sector.

Overall, the fourth quarter of 2024 was a period of significant progress and achievement for OPKO Health. Through strategic collaborations, innovative research and development efforts, and financial restructuring, the company is poised to continue its trajectory of success in the healthcare industry.